Project Grant R01HD120926
- The National Institute of Child Health and Human Development awarded Rowan University $408,380 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop hypoxia-responsive lipid nanoparticles for delivery of placental growth factor messenger RNA and soluble FMS-like tyrosine kinase-1 small interfering RNA to treat preeclampsia. The research addresses preeclampsia through targeted drug delivery to diseased placental tissue. The project...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development provides $769,916 to Emergent Biotechnologies LLC for research into a novel therapy for preeclampsia. The funding supports Phase 1 of developing and characterizing a handle region peptide as an innovative treatment for preeclampsia under the Child Health and Human Development Extramural Research program (CFDA 93.865). Phase 1 work will...
- The National Institute of Child Health and Human Development, an office of the Department of Health and Human Services, awarded $600,016 to the University of California, San Diego on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate extracellular vesicles as mediators of kidney damage in preeclampsia. The research employs a three-dimensional microfluidic human proximal tubule kidney-on-a-chip model to study how placental and serum...
- The National Institute of Child Health and Human Development awarded $668,485 to the University of California, San Diego on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate DNA repair mechanisms in hypoxia-induced placental genomic instability. The research examines increased genomic instability in placental villous tissue and trophoblast stem cells associated with maternal vascular malperfusion, a pattern of placental...
- The National Institute of Child Health and Human Development awarded Duke University $694,448 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct research analyzing local and global responses in the placenta syncytiotrophoblast. The research investigates the multinucleated syncytiotrophoblast, a giant single cell that separates maternal and fetal vasculature during pregnancy and performs critical functions including nutrient...
- The National Institute of Child Health and Human Development (NICHD) awarded a $411,125 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Syracuse University to develop a microfluidic human placenta organoid model. The goal is to generate human trophoblast stem cells (HTSCs) from induced pluripotent stem cells and use them to create a placenta organoid system that can replicate early/mid-gestation placental development. The researchers will study the role of...
- Federal Grant Award Summary The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded $429,000 in Project Grant funding to the University of Colorado-Denver for research conducted under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award was obligated on August 6, 2025, with a project completion date of July 31, 2027. This R21 mechanism grant supports research utilizing induced pluripotent stem cell (iPSC)...
- The National Institute of Child Health and Human Development awarded $453,698 to Brigham & Women's Hospital Inc. on August 20, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and validate chemogenetic animal models of preeclampsia for identifying novel pharmacological targets. The research exploits a transgenic mouse line expressing a recombinant yeast D-amino acid oxidase that generates hydrogen peroxide in vascular endothelium when...
- The National Institute of Child Health and Human Development (NICHD) awarded a $429,000 Project Grant (CFDA 93.865: Child Health and Human Development Extramural Research) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to develop a new imaging tool to assess placental hemodynamics during pregnancy. The study aims to determine if Subharmonic Aided Pressure Estimation (SHAPE) using contrast-enhanced ultrasound can provide a safe, non-invasive, and real-time method...
- The National Institute of Child Health and Human Development awarded the Regents of the University of Michigan $598,644 on July 8, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop a non-invasive ultrasound technique for detecting preeclampsia and fetal growth restriction through simultaneous assessment of maternal and fetal blood flow components in the placenta. The research uses spectral analysis of umbilical venous pulse wave patterns to...
The National Institute of Child Health and Human Development awarded $568,925 to the Board of Regents of the University of Nebraska on September 1, 2026, to conduct pharmacokinetic, pharmacodynamic, safety, and efficacy studies of targeted nanoparticle drug delivery to the placenta under CFDA 93.865 (Child Health and Human Development Extramural Research). The research addresses placental dysfunction, the underlying cause of preeclampsia, intrauterine growth restriction, and stillbirth, which affect up to 15 percent of pregnancies in the United States. The recipient, through its University of Nebraska Medical Center division in Omaha, Nebraska, will assess three drugs with proven efficacy in treating placental dysfunction—aspirin, melatonin, and SE175—delivered via targeted liposomes decorated with the placental homing peptide IRGD. The work will employ mouse models of healthy pregnancy and diet-induced placental dysfunction, human placental explant cultures, and computational modeling to quantify biodistribution and compare the safety and efficacy of targeted drug delivery against free drug administration. Biodistribution studies will measure drug concentrations in maternal, placental, and offspring tissues over time, with treatment studies comparing the effects of systemic versus targeted delivery approaches. The award period runs through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $568.9k | 8/31/26 |